TEVIMBRA

This brand name is authorized in Austria, Estonia, Croatia, Lithuania

Active ingredients

The drug TEVIMBRA contains one active pharmaceutical ingredient (API):

1 Tislelizumab UNII 0KVO411B3N - TISLELIZUMAB

Tislelizumab is a humanised immunoglobulin G4 (IgG4) variant monoclonal antibody against PD-1, binding to the extracellular domain of human PD-1. It competitively blocks the binding of both PD-L1 and PD-L2, inhibiting PD-1-mediated negative signalling and enhancing the functional activity in T cells in in vitro cell-based assays. Read about Tislelizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TEVIMBRA Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FF09		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3045945, 3045956
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097800, 1097801